Cerebral palsy: A rational approach to a treatment protocol and the role of botulinum toxin in treatment

Muscle and Nerve

Volumn 20, Issue SUPPL. 6, 1997, Pages

  Russman, Barry S ^a   Tilton, Ann ^b   Gormley Jr , Mark E ^c  

^a Shriner's Hospital   (United States)

^b CHILDREN S HOSPITAL   (United States)

^c GILLETTE CHILDREN'S SPECIALTY HEALTHCARE   (United States)

Author keywords

Botulinum toxin; Cerebral palsy; Chemodenervation; Contracture; Spasticity; Spasticity management

Indexed keywords

ANTIPARKINSON AGENT; BOTULINUM TOXIN;

CEREBRAL PALSY; CHILD; HUMAN; REVIEW;

ANTI-DYSKINESIA AGENTS; BOTULINUM TOXINS; CEREBRAL PALSY; CHILD; HUMANS;

EID: 0001126921     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Albright AL, Barren WB, Fasick MP, Polinko P, Janosky J: Continuous intrathecal baclofen infusion for spasticity of cerebral origin. JAMA 1993; 270:2475-2477.
2. Ashworth B: Preliminary trial of carisoprodal in multiple sclerosis. Practitioner 1964; 192:540.
3. Badell A: The effects of medications that reduce spasticity in the management of spastic cerebral palsy. J Neuro Rehab 1991; 5(Suppl 1):S13-S14.
4. Bergner M, Bobbitt RA, Carter WB, Gilson BS: The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981; 19:787-805.
5. Bleck EE: Orthopedic Management in Cerebral Palsy. Oxford, MacKeith Press, 1987.
6. Bobath B, Bobath K: The Neuro-development Treatment, in Scrutton D (ed): Management of the Motor Disorders of Children with Cerebral Palsy. Philadelphia, Lippincott, 1984, pp 6-18.
7. Bower E, McLellan DL: Measuring motor goals in children with cerebral palsy. Clinical Rehabilitation 1994; 8:198-206.
8. Breslau N, Staruch KS, Mortimer EA, Jr.: Psychological distress in mothers of disabled children. Am J Dis Child 1982; 136:682-686.
9. Brin MF: Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve 1997; 20 (suppl 6): S146-S168.
10. Calderon-Gonzalez R, Calderon-Sepulveda RF, Rinconreyes M, Garciaramirez J, Minoarango E: Botulinum toxin A in management of cerebral palsy. Pediat Neurol 1994; 10:284-288.
11. Chambers HG: The surgical treatment of spasticity. Muscle Nerve 1997; 20 (suppl 6): S121-S128.
12. Chutorian A, Root L: Management of spasticity in children with botulinum-A toxin. Intl Pediatrics 1994; 9:35-43.
13. Chutorian A, Root L, BTA Study Group: A multi-centered, randomized, double-blind, placebo-controlled trial of botulinum toxin type A in the treatment of lower limb spasticity in pediatric cerebral palsy. Mov Disord 1995; 10:364(Abstract).
14. Corry IS, Cosgrove AP, Walsh EG, McClean D, Graham HK: Botulinum toxin A in the hemiplegic upper limb: a double-blind trial. Dev Med Child Neurol 1997; 39:185-193(Abstract).
15. Cosgrove AP, Graham HK: Botulinum toxin A in the management of spasticity with cerebral palsy. Br J Surg 1992; 74-B:135-136.
16. Cosgrove AP, Graham HK: Botulinum toxin A prevents the development of contractures in the hereditary spastic mouse. Dev Med Child Neurol 1994; 36:379-385.
17. Davidoff RA: Antispasticity drugs: mechanisms of action. Ann Neurol 1985; 1:107-116.
18. Feldman AB, Haley SM, Coryell J: Concurrent and construct validity of the Pediatric Evaluation of Disability Inventory. Phys Ther 1990; 70:602-610.
19. Gracies J-M, Elovic E, McGuire J, Simpson DM: Traditional pharmacological treatments for spasticity part I: local treatments. Muscle Nerve 1997; 20 (suppl 6): S61-S91.
20. Koman LA, Mooney JF, III, Smith BP: Botulinum toxin: potential role in the management of cerebral palsy during childhood, in Jankovic J, Hallett M (eds): Therapy with Botulinum Toxin. New York, Marcel Dekker, 1994, pp 511-522.
21. Landau WM, Hunt CC: Dorsal rhizotomy a treatment of unproven efficacy [comment]. J Child Neurol 1990; 5:174-178.
22. Leach J: Children undergoing treatment with botulinum toxin: the role of the physical therapist. Muscle Nerve 1997; 20 (suppl 6): S194-S207.
23. McLaughlin JF, Bjornson KF, Astley SJ, Hays RM, Hoffinger SA, Armantrout EA, Roberts TS: The role of selective dorsal rhizotomy in cerebral palsy: critical evaluation of a prospective clinical series. Dev Med Child Neurol 1994; 36:755-769.
24. Nelson KB, Ellenberg JH: Epidemiology of cerebral palsy. Adv Neurol 1978; 19:421-435.
25. Nelson KB, Ellenberg JH: Children who "outgrew" cerebral palsy. Pediatrics 1982; 69:529-536.
26. Paine RS: Neurologic examination of infants and children. Ped Clin NA 1960; 7:471.
27. Peacock WJ, Staudt LA: Functional outcomes following selective posterior rhizotomy in children with cerebral palsy. J Neurosurg 1991; 74:380-385.
28. Pierson SH: Outcome measures in spasticity management. Muscle Nerve 1997; 20 (suppl 6): S36-S60.
29. Pollock N, Baptiste S, Law M, Opzoomer A, et al: Occupational performance measures: a review based on the guidelines for client-centered practice of occupational therapy. Can J Occupat Ther 1990; 57:77-81.
30. Rang M, Silver R, Ganza J: Cerebral Palsy, in Lovell WW, Winter RB (eds): Pediatric Orthopedics. Philadelphia, J.B. Lippincott, 1989.
31. Russell DJ, Rosenbaum PL, Cadman DT, Gowland C, Hardy S, Jarvis S: The gross motor function measure: a means to evaluate the effects of physical therapy. Dev Med Child Neurol 1989; 31:341-352.
32. Russman BS, Gage JR: Cerebral palsy. Curr Probl Pediatr 1989; 19:65-111.
33. Sussman MD: Casting as an adjunct to neurodevelopmental therapy for cerebral palsy. Dev Med Child Neurol 1983; 25:804-805.
34. Wall SA, Chait LA, Temlett JA, Perkins B, Hillen G, Becker P: Botulinum A chemodenervation: a new modality in cerebral palsied hands. Br J Plast Surg. 1993; 46:703-706.
35. Watt J, Sims D, Harckham F, et al: A prospective study of inhibitive casting as an adjunct physiotherapy in the cerebral palsied child. Orthopedic Transactions. 1984; 8:110.